As Pradaxa Lawsuits Move Forward, Bernstein Liebhard LLP Notes Manufacturer is Working on Possible Antidote for Internal Bleeding Caused by the Blood-Thinner
New York, New York (PRWEB) December 04, 2013 -- As nearly 2,000 Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) alleging injuries due to internal bleeding continue to move forward in federal court, Bernstein Liebhard LLP notes that Boehringer Ingelheim Pharmaceuticals, the manufacturer of the blood-thinner, has announced results from a clinical trial of a possible antidote to reverse dangerous internal bleeding that can sometimes accompany use of the drug. According to a recent Reuters report, the early stage trial involving 150 healthy volunteers indicated that the antidote worked “immediately and completely.” However, larger trials will be needed to prove the antidote’s safety and effectiveness.*
“This is an interesting development, as a lack of an effective antidote for internal bleeding is a key factor in hundreds of Pradaxa lawsuits currently pending against Boehringer Ingelheim. Unfortunately, the availability of any such antidote will have come too late for the alleged victims of Pradaxa,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Pradaxa bleeding side effects.
Pradaxa Lawsuits
According to court documents, just over 1,900 Pradaxa lawsuits are currently pending in the federal multidistrict litigation underway in U.S. District Court, Southern District of Illinois. All of the claims were filed on behalf of alleged victims of Pradaxa bleeding side effects. Among other things, the lawsuits allege that Boehringer Ingelheim failed to provide adequate warnings regarding the lack of an antidote for internal bleeding caused by the medication. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
According to Bernstein Liebhard, announcement of the possible antidote came a little over a month after a study conducted by the Institute for Safe Medicine Practices (ISMP) revealed that Pradaxa had been named in more adverse event reports than any other drug monitored by the U.S. Food & Drug Administration (FDA). According to the report, the FDA logged more than 3,200 Pradaxa side effect reports in 2012, including 582 that had fatal outcomes. The same year, warfarin, a much older blood thinner, was the subject of just 861 reports, including 56 deaths.**
Individuals who allegedly suffered serious Pradaxa bleeding side effects may be entitled to compensation for their injury-related damages. To learn more about filing a Pradaxa lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*reuters.com/article/2013/11/18/pradaxa-antidote-idUSL2N0J300920131118, Reuters November 19, 2013
**ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 17, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.pradaxalawsuithelp.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Pradaxa Lawsuit Information Center, http://www.pradaxalawsuithelp.com/, +1 800-511-5092, [email protected]
Share this article